Antonietta Vilella

Dr. Antonietta Vilella

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
MZMichele Zoli
Michele Zoli
SPSusanna Pucci
Susanna Pucci
AVAntonietta Vilella
Antonietta Vilella
CGCecilia Gotti
Cecilia Gotti
Neuronal nicotinic acetylcholine receptors (nAChRs) belong to a super-family of Cysloop ligand-gated ion channels that respond to endogenous acetylcholine (ACh) or other cholinergic ligands. These receptors are also the targets of drugs such as nicotine (the main addictive agent delivered by cigarette smoke) and are involved in a variety of physiological and pathophysiological processes. Numerous studies have shown that the expression and/or function of nAChRs is compromised in many neurological and psychiatric diseases. Furthermore, recent studies have shown that neuronal nAChRs are found in a large number of nonneuronal cell types including endothelial cells, glia, immune cells, lung epithelia and cancer cells where they regulate cell differentiation, proliferation and inflammatory responses. The aim of this review is to describe the most recent findings concerning the structure and function of native nAChRs inside and outside the nervous system.

1 September 2018 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Open access
AVAntonietta Vilella
Antonietta Vilella
DBDaniela Belletti
Daniela Belletti
ASAnn Katrin Sauer
Ann Katrin Sauer
SHSimone Hagmeyer
Simone Hagmeyer
TSTasnuva Sarowar
Tasnuva Sarowar
Andreas GrabruckerAndreas Grabrucker
Andreas Grabrucker
A local dyshomeostasis of zinc ions in the vicinity of amyloid aggregates has been proposed in Alzheimer's disease (AD) due to the sequestration of zinc in senile plaques. While an increase in zinc levels may promote the aggregation of amyloid beta (Aβ), increased brain zinc might also be beneficial rescuing some pathological alterations caused by local zinc deficiency. For example, increased Aβ degradation by metalloproteinases, and a reduction in inflammation can be hypothesized. In addition, zinc may allow a stabilization of the number of synapses in AD brains. Thus, to evaluate whether altering zinc-levels within the brain is a promising new target for the prevention and treatment of AD, we employed novel zinc loaded nanoparticles able to deliver zinc into the brain across the blood-brain barrier. We performed in vivo studies using wild type (WT) and APP23 mice to assess plaque load, inflammatory status and synapse loss. Furthermore, we performed behavioral analyses. After chronically injecting these nanoparticles for 14 days, our results show a significant reduction in plaque size and effects on the pro-inflammatory cytokines IL-6 and IL-18. On behavioral level we could not detect negative effects of increased brain zinc levels in APP23 mice and treatment with g7-NP-Zn normalized the observed hyperlocomotion of APP23 mice. Therefore, we conclude that a targeted increase in brain zinc levels may have beneficial effects in AD.

17 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GHGina P. Hoyos-Ceballos
Gina P. Hoyos-Ceballos
BRBarbara Ruozi
Barbara Ruozi
Ilaria OttonelliIlaria Ottonelli
Ilaria Ottonelli
FRFederica Da Ros
Federica Da Ros
MVMaria Angela Vandelli
Maria Angela Vandelli
BOBetty Lucy López Osorio
Betty Lucy López Osorio
The treatment of diseases that affect the central nervous system (CNS) represents a great research challenge due to the restriction imposed by the blood–brain barrier (BBB) to allow the passage of drugs into the brain. However, the use of modified nanomedicines engineered with different ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang–2), was conjugated to poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies. Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising brain drug delivery system.

1 June 2015 in Nanomedicine
Verified
Journal Article
Closed access
YMYuliana Monsalve
Yuliana Monsalve
Giovanni TosiGiovanni Tosi
Giovanni Tosi
BRBarbara Ruozi
Barbara Ruozi
DBDaniela Belletti
Daniela Belletti
AVAntonietta Vilella
Antonietta Vilella
LSLigia Sierra
Ligia Sierra
Drug targeting to the CNS is challenging due to the presence of blood-brain barrier. We investigated chitosan (Cs) nanoparticles (NPs) as drug transporter system across the blood-brain barrier, based on mAb OX26 modified Cs. Cs NPs functionalized with PEG, modified and unmodified with OX26 (Cs-PEG-OX26) were prepared and chemico-physically characterized. These NPs were administered (intraperitoneal) in mice to define their ability to reach the brain. Brain uptake of OX26-conjugated NPs is much higher than of unmodified NPs, because: long-circulating abilities (conferred by PEG), interaction between cationic Cs and brain endothelium negative charges and OX26 TfR receptor affinity. Cs-PEG-OX26 NPs are promising drug delivery system to the CNS.

1 January 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
AVAntonietta Vilella
Antonietta Vilella
Giovanni TosiGiovanni Tosi
Giovanni Tosi
Andreas GrabruckerAndreas Grabrucker
Andreas Grabrucker
BRBarbara Ruozi
Barbara Ruozi
DBDaniela Belletti
Daniela Belletti
MZMichele Zoli
Michele Zoli

1 March 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
Giovanni TosiGiovanni Tosi
Giovanni Tosi
AVAntonietta Vilella
Antonietta Vilella
RCResham Chhabra
Resham Chhabra
MSMichael J. Schmeisser
Michael J. Schmeisser
TBTobias M. Boeckers
Tobias M. Boeckers
Andreas GrabruckerAndreas Grabrucker
Andreas Grabrucker